122 related articles for article (PubMed ID: 8189055)
1. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli.
Gruber M; Schodin BA; Wilson ER; Kranz DM
J Immunol; 1994 Jun; 152(11):5368-74. PubMed ID: 8189055
[TBL] [Abstract][Full Text] [Related]
2. Properties of bispecific single chain antibodies expressed in Escherichia coli.
Kranz DM; Gruber M; Wilson ER
J Hematother; 1995 Oct; 4(5):403-8. PubMed ID: 8581376
[TBL] [Abstract][Full Text] [Related]
3. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells.
Cho BK; Roy EJ; Patrick TA; Kranz DM
Bioconjug Chem; 1997; 8(3):338-46. PubMed ID: 9177839
[TBL] [Abstract][Full Text] [Related]
4. Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria.
Kurucz I; Titus JA; Jost CR; Jacobus CM; Segal DM
J Immunol; 1995 May; 154(9):4576-82. PubMed ID: 7536774
[TBL] [Abstract][Full Text] [Related]
5. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibody-mediated lysis of placental and germ cell alkaline phosphatase targeted solid tumors in immunocompetent mice.
Smans KA; Hoylaerts MF; Narisawa S; Millán JL; De Broe ME
Cancer Res; 1995 Oct; 55(19):4383-90. PubMed ID: 7671251
[TBL] [Abstract][Full Text] [Related]
7. Redirection of T cell-mediated cytotoxicity by a recombinant single-chain Fv molecule.
George AJ; Titus JA; Jost CR; Kurucz I; Perez P; Andrew SM; Nicholls PJ; Huston JS; Segal DM
J Immunol; 1994 Feb; 152(4):1802-11. PubMed ID: 8120389
[TBL] [Abstract][Full Text] [Related]
8. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.
Bruenke J; Fischer B; Barbin K; Schreiter K; Wachter Y; Mahr K; Titgemeyer F; Niederweis M; Peipp M; Zunino SJ; Repp R; Valerius T; Fey GH
Br J Haematol; 2004 Apr; 125(2):167-79. PubMed ID: 15059139
[TBL] [Abstract][Full Text] [Related]
9. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
10. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
11. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
Chamow SM; Zhang DZ; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
J Immunol; 1994 Nov; 153(9):4268-80. PubMed ID: 7930627
[TBL] [Abstract][Full Text] [Related]
12. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
13. Tumor therapy with bispecific antibody: the targeting and triggering steps can be separated employing a CD2-based strategy.
Wild MK; Strittmatter W; Matzku S; Schraven B; Meuer SC
J Immunol; 1999 Aug; 163(4):2064-72. PubMed ID: 10438945
[TBL] [Abstract][Full Text] [Related]
14. Creating CTL targets with epitope-linked beta 2-microglobulin constructs.
Uger RA; Barber BH
J Immunol; 1998 Feb; 160(4):1598-605. PubMed ID: 9469415
[TBL] [Abstract][Full Text] [Related]
15. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies.
Lindhofer H; Mocikat R; Steipe B; Thierfelder S
J Immunol; 1995 Jul; 155(1):219-25. PubMed ID: 7602098
[TBL] [Abstract][Full Text] [Related]
16. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Brischwein K; Schlereth B; Guller B; Steiger C; Wolf A; Lutterbuese R; Offner S; Locher M; Urbig T; Raum T; Kleindienst P; Wimberger P; Kimmig R; Fichtner I; Kufer P; Hofmeister R; da Silva AJ; Baeuerle PA
Mol Immunol; 2006 Mar; 43(8):1129-43. PubMed ID: 16139892
[TBL] [Abstract][Full Text] [Related]
17. Functional humanization of an anti-CD16 Fab fragment: obstacles of switching from murine {lambda} to human {lambda} or {kappa} light chains.
Schlapschy M; Fogarasi M; Gruber H; Gresch O; Schäfer C; Aguib Y; Skerra A
Protein Eng Des Sel; 2009 Mar; 22(3):175-88. PubMed ID: 19022801
[TBL] [Abstract][Full Text] [Related]
18. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
[TBL] [Abstract][Full Text] [Related]
19. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
[TBL] [Abstract][Full Text] [Related]
20. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway.
Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E
Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
